Showing 10,661 - 10,680 results of 18,308 for search 'significant ((((step decrease) OR (((teer decrease) OR (a decrease))))) OR (mean decrease))', query time: 0.80s Refine Results
  1. 10661
  2. 10662

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  3. 10663

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  4. 10664

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  5. 10665

    Supplementary Table 1–9. by Yu Wang (12152)

    Published 2025
    “…Furthermore, a decrease in total cholesterol exhibited a causal effect on sepsis in multivariable MR (OR 0.779, 95% CI 0.642–0.944; P = 0.01). …”
  6. 10666

    STROBE-MR checklist. by Yu Wang (12152)

    Published 2025
    “…Furthermore, a decrease in total cholesterol exhibited a causal effect on sepsis in multivariable MR (OR 0.779, 95% CI 0.642–0.944; P = 0.01). …”
  7. 10667

    Instrumental Variables details of lipids. by Yu Wang (12152)

    Published 2025
    “…Furthermore, a decrease in total cholesterol exhibited a causal effect on sepsis in multivariable MR (OR 0.779, 95% CI 0.642–0.944; P = 0.01). …”
  8. 10668

    Datasheet1_Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicen... by Zeng Li (688702)

    Published 2024
    “…The activated partial thromboplastin time in the treatment group decreased significantly (P < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.…”
  9. 10669

    Datasheet2_Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicen... by Zeng Li (688702)

    Published 2024
    “…The activated partial thromboplastin time in the treatment group decreased significantly (P < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.…”
  10. 10670

    Datasheet1_Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicen... by Zeng Li (688702)

    Published 2024
    “…The activated partial thromboplastin time in the treatment group decreased significantly (P < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.…”
  11. 10671

    Datasheet2_Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicen... by Zeng Li (688702)

    Published 2024
    “…The activated partial thromboplastin time in the treatment group decreased significantly (P < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.…”
  12. 10672

    Data Sheet 1_Retroperitoneal fibrosis in presence of autoimmune coagulation factor XIII deficiency result in recurrent critical post-operative hemorrhage: a case report and molecul... by Tomonori Matsushita (1682554)

    Published 2025
    “…We investigated the potential involvement of IgG4-related disease and the effects of IgG4 on coagulation Factor XIII using an in vitro system, and it was demonstrated that both IgG1 and IgG4 recognized the A subunit of coagulation Factor XIII. The purified IgG antibody samples containing IgG1 and IgG4 were shown to significantly reduce the function of coagulation Factor XIII derived from healthy individuals. …”
  13. 10673

    Table 1_Does screening mode matter? A repeated cross-sectional study of computer self-administered vs. clinician-administered screening of youth substance use in pediatric primary... by Chloe Gao (11107228)

    Published 2025
    “…Patients responded to the Car, Relax, Alone, Forget, Family/Friends, and Trouble (CRAFFT), a well-validated adolescent substance use screening tool that measures past-12-month alcohol, cannabis, and other substance use (“anything else to get high”). …”
  14. 10674

    Data Sheet 1_An alternative structured weight management protocol to rapid weight loss in mixed martial arts: a prospective interventional study of pre-competition weight managemen... by Clóvis Albuquerque Maurício (22389121)

    Published 2025
    “…For MMA athletes, adhering to an evidence-based Weight Management Protocol (WMP), targeting a 10% body weight reduction within 7 days prior to weigh-in, poses a significant challenge. …”
  15. 10675

    Controller parameters of two control methods. by Bo Zhang (6559)

    Published 2025
    “…Numerical simulations confirm the superiority of the proposed control method, with results showing an reduction in settling time and a decrease in peak overshoot compared to conventional PD control. …”
  16. 10676

    The diagram of flexible spacecraft system. by Bo Zhang (6559)

    Published 2025
    “…Numerical simulations confirm the superiority of the proposed control method, with results showing an reduction in settling time and a decrease in peak overshoot compared to conventional PD control. …”
  17. 10677

    Data Sheet 1_Effects of sodium tanshinone IIA sulfonate injection on pro-inflammatory cytokines, adhesion molecules and chemokines in Chinese patients with atherosclerosis and athe... by Fan Xie (562816)

    Published 2025
    “…</p>Conclusion<p>The use of STS in patients with AS and ASCVD appeared to significantly decrease levels of pro-inflammatory cytokines, adhesion molecules, and chemokines.…”
  18. 10678

    Supplementary Material for: Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio... by figshare admin karger (2628495)

    Published 2025
    “…In VOYAGE I, NLR (p=0.011), PLR (p=0.015) and MLR (p=0.004) decreased significantly following 16 weeks of guselkumab treatment vs. placebo. …”
  19. 10679

    Smart spot and smart triage platform. by Rebecca Goertzen (22008461)

    Published 2025
    “…The inpatient mortality rate decreased from 5.1% in August 2018 to 2.6% in October 2023, with a significant increase in the number of cases with comparable illness severity.…”
  20. 10680

    HICH patient demographics during QI intervention. by Rebecca Goertzen (22008461)

    Published 2025
    “…The inpatient mortality rate decreased from 5.1% in August 2018 to 2.6% in October 2023, with a significant increase in the number of cases with comparable illness severity.…”